Lauren Kelly, NP
Adult Health · Lincoln, NENPI 1568793057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 39.9% of the total. Reporting peaked in 2023 at $755 and has fallen 67.1% since, to $248 in 2025.
Across 87 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$538
- Alkermes, Inc.$217
- Corium, LLC$107
- E.r. Squibb & Sons, L.L.C.$76
- Jazz Pharmaceuticals Inc.$63
- Johnson & Johnson$54
- plus $293 from 10 others
What the payments were for
- Food & beverage$1,30096%
- Education$494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,349 in reported general payments places this provider in the 75th percentile of 58 adult health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 11 | $37,926 |
| VraylarCariprazine Hcl | 21 | $27,946 |
| Aripiprazole | 59 | $4,726 |
| Paliperidone ErPaliperidone | 13 | $1,646 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 37 | $1,455 |
| Carbamazepine | 12 | $953 |
| Olanzapine | 20 | $796 |
| Lamotrigine | 71 | $735 |
| Fluoxetine Hcl | 15 | $717 |
| Buspirone Hcl | 46 | $699 |
| Hydroxyzine Hcl | 22 | $469 |
| Trazodone Hcl | 46 | $402 |
| Modafinil | 12 | $358 |
| Duloxetine Hcl | 22 | $317 |
| Bupropion XlBupropion Hcl | 24 | $296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $54 | $37,92611 claims |
| AbbVieVraylar | $42 | $27,94621 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $3014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 58 adult health providers in Nebraska.
Other adult health in Lincoln
- Amy KingLincoln$7K
- Heather MosleyLincoln$6K
- Korinne MurcekLincoln$4K
- Stacy SveenLincoln$3K
- Mary BaxterLincoln$3K
- Shirley Mohr-BurtLincoln$2K
- Jessica MattisonLincoln$2K
- Kelly FieldsLincoln$2K
- Thien KieuLincoln$2K
- Rhonda OlmstedLincoln$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.